The most widely used radioisotope for diagnostic imaging. NorthStar's platform technology is applicable to the separation of Tc99m from Mo99. All Mo99 is produced outside the United States using highly enriched uranium at aging reactors. NorthStar expects to be the first domestic supplier of Mo99 and will not use any uranium in its process.
Ac225/Bi213 (Research and Development purposes only)
Potential uses for cancer related therapies and infectious diseases such as HIV. NorthStar's platform technology is applicable to the separation of Bi213 from Ac225. Ac225 is in short supply with an extremely high cost of the isotope. NorthStar has developed an Ac225 production process that allows for more Ac225 production in one day than the current annual production worldwide.
W188/Re188 (future offering)
Potential use in treatment of skin cancers. NorthStar's platform technology is applicable to the separation of Re188 from W188. Current Re188 generators produce a lower than desired specific activity of the final Re188 product. RheniGen solves this challenge by producing a high specific activity Re188 solution.
Ge68/Ga68 (future offering)
Potential imaging agent and could also be used to treat some cancer tumors. NorthStar's platform technology can be applied to this radioisotope pair producing a high specific activity Ga68 product for clinical use.
Th227/Ra223 (future offering)
NorthStar has proven technology for the separation of either or both of these radioisotopes from the parent Ac227 for clinical use. In both cases, our technology can produce a high purity product with high specific activity. NorthStar also has a production technology (Ac225) applicable for producing Ac227.